|
gptkbp:instanceOf
|
small molecule
antiviral drug
|
|
gptkbp:administeredBy
|
capsule
|
|
gptkbp:approvedBy
|
gptkb:India
gptkb:Japan
gptkb:United_Kingdom
gptkb:United_States
2021
|
|
gptkbp:ATCCode
|
J05AX27
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:CASNumber
|
2349386-89-4
|
|
gptkbp:chemicalClass
|
antiviral drug
|
|
gptkbp:chemicalFormula
|
nucleoside analog prodrug
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:contraindication
|
children
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Emory_University
gptkb:Merck_&_Co.
gptkb:Ridgeback_Biotherapeutics
|
|
gptkbp:discoveredIn
|
gptkb:Emory_Institute_for_Drug_Development
|
|
gptkbp:eliminatedIn
|
urine
|
|
gptkbp:firstSynthesized
|
2019
|
|
gptkbp:halfLife
|
3.3 hours
|
|
gptkbp:hasMolecularFormula
|
C13H19N3O7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
molnupiravir
|
|
gptkbp:indication
|
mild to moderate COVID-19
adults at risk of severe COVID-19
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
RNA-dependent RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
gptkb:Emory_University
gptkb:Merck_&_Co.
gptkb:Ridgeback_Biotherapeutics
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:prodrugOf
|
gptkb:N4-hydroxycytidine
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
dizziness
headache
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:synonym
|
gptkb:Lagevrio
gptkb:EIDD-2801
gptkb:MK-4482
|
|
gptkbp:targetsVirus
|
gptkb:COVID-19
|
|
gptkbp:usedFor
|
gptkb:COVID-19
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:COVID-19_treatments
gptkb:Lagevrio
gptkb:Ridgeback_Biotherapeutics
|
|
gptkbp:bfsLayer
|
6
|